Your browser doesn't support javascript.
loading
Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort.
Decker, Slade; Xiao, Shaoming; Dillen, Carly; Schumacher, Christina M; Milstone, Aaron M; Frieman, Matthew; Debes, Amanda K.
  • Decker S; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Xiao S; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Dillen C; Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Schumacher CM; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Milstone AM; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Frieman M; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Debes AK; Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Open Forum Infect Dis ; 11(2): ofad625, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38352152
ABSTRACT
Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Año: 2024 Tipo del documento: Article